Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 dose-escalation and expansion study of EO-3021 in CLDN18.2-expressing solid tumors
jRCT2031230637Phase 1Completed
- Sponsor
- Elevation Oncology, Inc.
- Start
- Jan 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of SYSA1801 in Nonhematologic neoplasms, gastric cancer (GC), esophagogastric junction cancer and 2 more, sponsored by Elevation Oncology, Inc. Primary endpoints: Dose-limiting toxicities, Treatment-emergent adverse events and 3 more. Started Jan 2024; status: completed.
02
Drugs
SYSA1801
03
Conditions
Nonhematologic neoplasmsgastric cancer (GC)esophagogastric junction cancerpancreatic cancer (PC)esophageal cancer
Beyond the preview
Go deeper on jRCT2031230637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230637.